12 results about "Canine coronavirus" patented technology

The invention discloses a monoclonal antibody for resisting canine coronavirus N protein, a detection reagent and application of the monoclonal antibody and the detection reagent. The monoclonal antibody for resisting the canine coronavirus N protein comprises a heavy chain variable region and a light chain variable region, the amino acid sequence of the heavy chain variable region is as shown in SEQ ID No. 1; the amino acid sequence of the light chain variable region is as shown in SEQ ID No.2. The monoclonal antibody with high affinity and detection sensitivity to canine coronavirus N protein lays a foundation for research, development and popularization of colloidal gold test strips and fluorescence immunoassay test strips.

The application discloses application of monensin in preparation of anti-coronavirus drugs, relates to the technical field of new monensin purposes, and the coronavirus has a ribosome frameshift translation regulation mechanism, monensin is used for inhibiting ribosome frameshift, and then inhibiting the coronavirus proliferation. For feline infectious peritonitis virus, the effective concentration of monensin is 0.1 muM-10 muM. For canine coronavirus, the effective concentration of monensin is 0.5 muM-10 muM. The application has the following advantages: small drug resistance risk; low effective concentration; and convenient administration.

The application belongs to the technical field of biological detection, and particularly relates to a combination of monoclonal antibodies against nucleocapsid protein of canine distemper virus and application. The combination is composed of monoclonal antibodies 1C8 and 1G8, and the sequences of the heavy chain and light chain variable region complement determining regions are clear (as shown in SEQ ID NO. 1-12, respectively), which endow the combination with high affinity and specificity. It has been verified that the combination can specifically recognize CDV-NP, and has no cross reaction with irrelevant antigens such as canine parainfluenza virus, canine coronavirus and canine parvovirus, thereby guaranteeing the specificity of detection from the source. The antibody combination can be used for preparing colloidal gold detection test strips, kits and other detection tools. The colloidal gold detection test strip based on the double antibody sandwich method uses 1C8 as a capture antibody and 1G8 as a labeled antibody, and is simple to operate, intuitive in results, does not require professional equipment, and is suitable for rapid screening in the field.

The invention provides a reagent and a kit for detecting canine coronavirus nucleic acid and application of the reagent and the kit. The reagent comprises a reagent for detecting a first region of the canine coronavirus, and the first region is selected from any fragment in SEQ ID NO: 1. By applying the reagent or the kit provided by the invention, the canine coronavirus can be accurately, quickly and sensitively identified.

The invention discloses application of monensin in preparation of an anti-coronavirus drug, and relates to the technical field of new application of monensin, coronavirus has a translation regulation mechanism of ribosome frame shift, and monensin is used for inhibiting ribosome frame shift so as to inhibit proliferation of the coronavirus. For the cat infectious peritonitis virus, the effective concentration of the monensin is 0.1 mu M to 10 mu M. For canine coronavirus, the effective concentration of the monensin is 0.5-10 [mu] M. The invention has the following advantages: the drug resistance risk is small; the effective concentration is low; the administration is convenient.

This application belongs to the field of in vitro detection technology, specifically relating to a fluorescent immunochromatographic kit for detecting canine parvovirus, canine coronavirus, and Giardia virus, as well as its preparation method and application. This application provides a fluorescent immunochromatographic kit for detecting canine parvovirus, canine coronavirus, and Giardia virus. Through a triple detection system design, it can simultaneously detect three important pathogens: canine parvovirus, canine coronavirus, and Giardia virus, improving detection efficiency and providing more comprehensive information for clinical diagnosis. Furthermore, by adding metal chelating agents and lysis agents to the sample diluent, metal ion impurities in the sample that cause non-specific binding can be specifically chelated, effectively eliminating interference and significantly improving the detection rate of the target pathogens while enhancing detection sensitivity, thus meeting the needs of rapid on-site screening in canine clinics.

The invention discloses application of long-chain non-coding RNA (LncRNA) XR002626937.1 in regulation and control of replication of canine coronavirus (CCoV), and belongs to the technical field of biological medicine. The nucleotide sequence of the LncRNA XR002626937.1 is as shown in SEQ ID No.1, is mainly positioned in a cell nucleus, is remarkably up-regulated in time and dose dependence after MDCK cells are infected by CCoV, and is positively correlated with virus load. Functional experiments prove that overexpression of the LncRNA can significantly promote CCoV replication, and knock-down of the expression of the LncRNA can effectively inhibit virus proliferation; the action mechanism comprises the steps of inhibiting activation of a p53 signal channel and downstream target genes p21 and Bax, repressing apoptosis of infected cells, antagonizing expression of natural immune factors such as RIG-I, MAVS, ISG15 and the like, promoting virus immune escape, and being capable of serving as competitive endogenous RNA to adsorb miR-10926-z to regulate and control the downstream signal channel. The key function of the LncRNA XR002626937.1 in CCoV infection is defined for the first time, a new target spot and a theoretical basis are provided for developing the anti-CCoV medicine targeting the LncRNA, and the application prospect is wide.

The application discloses a quadruple RT-qPCR method for simultaneously detecting canine digestive tract viruses, a kit and application, and the real-time fluorescent quantitative PCR detection kit comprises PCR primer probes, the PCR primer probes comprise forward PCR amplification primers, reverse PCR amplification primers and detection probes respectively for canine parvovirus, canine coronavirus, canine adenovirus type 1 and canine rotavirus; the sequences are shown in SEQ ID NO. 1 to SEQ ID NO. 12, respectively, the application can detect canine parvovirus, canine coronavirus, canine adenovirus type 1 and canine rotavirus, has very high sensitivity and specificity, and is favorable for early diagnosis or treatment of sick dogs.

This invention discloses a triple lyophilized fluorescent PCR rapid detection kit for canine distemper virus, canine coronavirus, and canine parvovirus, belonging to the field of rapid detection kit technology. It includes a housing, protective components, and a sample collection mechanism. The back of the housing is symmetrically fitted with hinges via bolts. This triple lyophilized fluorescent PCR rapid detection kit for canine distemper virus, canine coronavirus, and canine parvovirus, through its primer, fluorescent probe, and reagent carrier components and sample collection mechanism, enables the rapid screening of three highly pathogenic canine viruses (canine distemper virus CDV, canine coronavirus CCV, and canine parvovirus CPV) using a lyophilization process based on quantitative real-time PCR technology.

The application belongs to the technical field of biomedical detection, and discloses an antibody pair against canine coronavirus N protein, a preparation method thereof, a nucleic acid molecule, a cell strain and application. The antibody pair or antigen binding fragment thereof comprises a first antibody or antigen binding fragment thereof, wherein the first antibody or antigen binding fragment thereof comprises amino acid sequences of heavy chain variable region complementarity determining regions 1-3 as shown in SEQ ID NO: 1-3, and amino acid sequences of light chain variable region complementarity determining regions 1-3 as shown in SEQ ID NO: 4-6; and a second antibody or antigen binding fragment thereof, wherein the second antibody or antigen binding fragment thereof comprises amino acid sequences of heavy chain variable region complementarity determining regions 1-3 as shown in SEQ ID NO: 7-9, and amino acid sequences of light chain variable region complementarity determining regions 1-3 as shown in SEQ ID NO: 10-12. The antibody pair provided by the application has a high titer, and has strong binding capacity with canine coronavirus N protein, and can realize high specificity and high sensitivity detection of canine coronavirus without interference of other viruses and drugs.

The application discloses a canine leptospira, icterohaemorrhagia leptospira and canine coronavirus triple inactivated vaccine. The application is prepared by adding adjuvant after inactivation of the canine leptospira, icterohaemorrhagia leptospira and canine coronavirus epidemic strain separated in China. The application relates to a pathogen separation culture, identification, inactivation method, production process, vaccine storage and immunization method. The canine triple inactivated vaccine is used for preventing canine leptospira disease, icterohaemorrhagia leptospira disease and canine coronavirus disease, and high antibodies can be generated after immunization of the canine, and the high antibodies have a good protective effect on virulent attack. The leptospira is a zoonosis, the canine is a companion animal of human, and the pet canine is in close contact with human, so the triple inactivated vaccine has good social benefits and important public health significance.